Skip to content

Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy

Effect of New Posterior Reconstruction Method on Recovery of Continence After Robot-assisted Laparoscopic Prostatectomy: Prospective, Single-blinded, Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01714219
Enrollment
100
Registered
2012-10-25
Start date
2012-10-31
Completion date
2014-03-31
Last updated
2014-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Localized Prostate Cancer, Urinary Incontinence

Keywords

prostatic neoplasms, prostatectomy, robotics, urinary incontinence

Brief summary

Incontinence is one of the most common complications of radical prostatectomy. The continence rate is not significantly improved even by robot-assisted laparoscopic prostatectomy (RALP). However, some reports suggested that posterior reconstruction (PR) behind vesicourethral anastomosis could improve early recovery of continence during open, laparoscopic or robot-assisted radical prostatectomy. But, recent prospective studies reported no benefit of PR after RALP, which was the opposite result of those of previous studies. However the PR techniques used in these prospective studies seem to be quite different from the previous techniques. They seem to have used single-step PR, which opposes the median dorsal fibrous raphe (MDFR) only to the Denonvilliers' fascia (DF). By contrast, the original technique incorporated additional reconstruction between the MDFR and the posterior bladder wall 1-2 cm from the new bladder neck. Our group identified this anatomic structure as the posterior counterpart of the detrusor apron (PDA). The PDA is a strong, thick functional tissue containing muscle that is more appropriate for pulling and fixing the MDFR than the DF. As such, we hypothesized that the key proximal structure for PR is not DF, but rather PDA. Furthermore, single-step reconstruction between MDFR and PDA could be enough for PR. We previously investigated whether our new PR technique, which entails opposition of the MDFR solely to the PDA, would improve continence recovery compared with the standard RALP technique without PR. And our retrospective study demonstrated that this new PR technique during RALP significantly shortens the time to the recovery of continence compared with the standard technique, which does not incorporate PR (Int J Urol, 2012;19:683-7). Thus, we plan to validate this result by a well-designed, prospective, randomized controlled study.

Interventions

Sponsors

Seoul National University Bundang Hospital
CollaboratorOTHER
Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Healthy volunteers
No

Inclusion criteria

* pathologically proven localized prostate cancer (≤cT3a) * patients to undergo robot-assisted laparoscopic prostatectomy by a single surgeon (Sang Eun Lee)

Exclusion criteria

* prior hormone therapy * prior radiation treatment on prostate or pelvis * preoperative urinary incontinence * refused to participate

Design outcomes

Primary

MeasureTime frameDescription
Complete recovery of urinary continence6 monthsDuration of complete continence recovery defined as no pad use measured by question 5 of EPIC questionnaire.

Secondary

MeasureTime frameDescription
Complication6 monthsComplication by modified Clavien-Dindo grade
Duration of social continence recovery6 monthsDefined as 0 or 1 measured by EPIC question 5.
Continence score at 3 months3 monthsBy EPIC question 5. * 0 vs. 1-3 * mean value
Estimated blood lossAt the day of surgery
Self perception (QoL) of urinary function at 3 months3 monthsBy EPIC question 7, * 0-1 vs. 2-4 * mean value
Total operative timeAt the day of surgery* Total operative time * Console time
Urinary leak at 3 months3 monthsBy EPIC question 1, * 1-3 vs. 4-5 * mean value

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026